Insmed (INSM) Jumps to $149.20 High After FDA Approval of Brinsupri
Insmed Inc. (NASDAQ:INSM) is a global biopharmaceutical company dedicated to transforming the lives of patients with serious and…
Ocular Therapeutix (OCUL) Raises $475M to Fund Phase 3 Axpaxli Trials
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye…
Novavax (NVAX) Expands $200M Sanofi Deal With Matrix-M Adjuvant
Novavax Inc. (NASDAQ:NVAX) is a biotechnology company headquartered in Gaithersburg, Maryland, that has built its reputation on advancing…
Recursion Pharmaceuticals (RXRX) Could Double With $8 Price Target
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company that has emerged as one of the pioneers of…
Dermata (DRMA) Wins Australian Patent for Acne Therapy
Dermata Therapeutics Inc. (NASDAQ:DRMA) is a San Diego–based clinical-stage biotechnology company dedicated to transforming the treatment of dermatological…
Kazia (KZIA) Trades Under $1 While Tackling Cancers With <1-Year Survival Rates
Kazia Therapeutics Limited (NASDAQ:KZIA) is a clinical-stage biotechnology company headquartered in Sydney, Australia, with a dedicated focus on…
CorMedix (CRMD) Revenue to Hit $350M After Melinta Buyout
CorMedix Inc. (NASDAQ: CRMD) is a biopharmaceutical company headquartered in Berkeley Heights, New Jersey, dedicated to the development…
Halozyme (HALO) Reports $1.179B Revenue and 65% Royalty Growth
Halozyme Therapeutics Inc. (NASDAQ:HALO) is a biotechnology company headquartered in San Diego, California, that has become a recognized…
Corcept (CORT) Skyrockets 1,534% in 10 Years
Corcept Therapeutics Inc. (NASDAQ:CORT) is a commercial-stage pharmaceutical company founded in 1998 and headquartered in Menlo Park, California.…
Health Care ETF (XLV) Beats S&P 500 in 15 of the Last 25 Years
The Health Care Select Sector SPDR Fund (NYSE:XLV) is one of the most widely recognized exchange-traded funds providing…
Cadrenal (CVKD) Targeted at $30 After Acquiring Phase 2-Ready Frunexian
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company focused on addressing critical unmet needs in cardiovascular medicine,…
Pfizer (PFE) Secures $70B R&D Push
Pfizer Inc. (NYSE:PFE) is one of the world’s most established and influential pharmaceutical companies, with a history spanning…